This bill adds new coverage requirements to Washington law by inserting a new section into chapter 48.43 RCW and a new section into chapter 74.09 RCW, and by reenacting and amending RCW 41.05.017. For health plans issued or renewed on or after January 1, 2026, health carriers must cover diagnosis and treatment of the chronic disease of obesity, including intensive health behavior and lifestyle treatment, metabolic and bariatric surgery, and FDA‑approved obesity medications. The bill prohibits coverage criteria for FDA‑approved obesity medications from being more restrictive than the FDA‑approved indications and requires that deductibles, copayments, coinsurance, and benefit year maximums for obesity treatment not be different or separate from coverage for other illnesses or conditions. Utilization management may be used to determine medical necessity only if appropriateness and medical necessity determinations are made in the same manner as for treatment of any other covered illness, condition, or disorder. The bill defines the covered categories and references CDC‑certified or recognized interventions and current clinical standards for intensive behavioral treatment, and it references telemedicine definitions by cross‑citation. The bill also requires the unspecified "authority" to apply to the federal Centers for Medicare and Medicaid Services (CMS) by November 1, 2025 for authorization to receive matching federal funds to provide the listed obesity services under chapter 74.09. Upon federal authorization from CMS, the authority and all managed care organizations must provide the same categories of obesity treatment with the same restrictions and utilization management provisions as in the new chapter 48.43 section. The enactment reenacts and amends RCW 41.05.017 to make health plans under that chapter subject to a listed set of RCW provisions, including the new section created by this act. The text provided does not identify which specific state agency is meant by "the authority," does not include the cross‑referenced telemedicine definitions, does not include the prior or surrounding language of RCW 41.05.017 so the full effect of that reenactment/amendment is unclear, and does not state whether or when federal authorization from CMS will be granted or any contingencies if authorization is not granted.

If enacted, most commercial health plans sold or renewed on or after January 1, 2026 will have to cover diagnosis and treatment for obesity — including intensive behavioral or lifestyle programs, metabolic and bariatric surgery, and FDA‑approved obesity drugs — without treating that coverage differently for deductibles, copays, coinsurance, or annual limits, and without drug coverage criteria more restrictive than the FDA label. In practice this will expand access for people with obesity and reduce barriers to medications and surgery, while creating new coverage responsibilities and likely higher claim costs for health carriers and employers that provide benefits; carriers may use utilization management but must apply it the same way they do for other conditions, and plan designs or premiums could change to accommodate the added expenses. For publicly funded care, the state authority named in the bill must apply to CMS by November 1, 2025 for matching federal funds, and if federal approval is granted Medicaid and its managed care organizations would be required to provide the same obesity services, likely increasing state and federal spending and administrative work for managed care plans. Important uncertainties remain in the text provided: the bill does not identify which specific state agency is "the authority," does not include the telemedicine definitions it references, and does not guarantee that CMS will authorize federal matching funds, so the Medicaid effects and timing are not certain.